Protocol Title: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

Target Population: Platinum-Resistant Ovarian Cancer

Summary: This randomized phase II/III trial studies how well Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and/or Bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back.

Key Inclusion Criteria:
- Submission of tumor tissue is required for all patients
- High grade Ovarian Cancer, including high grade serous; clear cell; endometrioid, grade 3; and others (adenocarcinoma, nitric oxide synthase [NOS]; mixed epithelial carcinoma; undifferentiated carcinoma);
  - NOTE: low grade serous, mucinous and carcinosarcoma histologies are excluded
- Recurrent, Platinum Resistant Ovarian Cancer (defined as progression within < 6 Months from completion of platinum based therapy; date should be calculated from the last administered dose of platinum therapy)
- 1-2 prior regimens (including primary therapy)
- Measurable disease defined by RECIST v. 1.1 or evaluable disease
- Performance status 0, 1 or 2
- Adequate hematologic, renal, and hepatic function within 14 Days prior to registration

Key Exclusion Criteria:
- Prior allogeneic bone marrow transplantation or prior solid organ transplantation
- Systemic anticancer therapy within 3 Weeks prior to entering the study
- Hormonal therapy within 1 Week prior to entering the study
- Prior treatment with anti-PD1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents
- Prior treatment with Bevacizumab (or any other anti-vascular therapy, e.g., Cediranib) for platinum resistant recurrence
- Prior treatment with PLD
- Prior radiotherapy to the abdomen or pelvis
- Known primary CNS malignancy or symptomatic CNS metastases are excluded, with exceptions
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
- Requiring treatment with a receptor activator of RANKL Inhibitor (e.g. Denosumab) who cannot discontinue it before treatment with Atezolizumab
- Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease
- History or risk of autoimmune disease
- History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan
  - History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Active tuberculosis (TB) are excluded

Contacts:
Principal Investigator: Katrina Wade, MD
Research Nurses (RN): Amanda Struckhoff (amanda.struckhoff@ochsner.org, ext. 23682)
Elsa Levenes (elsa.levenes@ochsner.org, ext. 21094)

For additional information: https://clinicaltrials.gov/ct2/show/NCT02839707

IRB# 2018.028